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Background and purpose: Citrulline is an amino acid which is produced by the urea cycle and also a
precursor for NO, that is, a vasodilator for normal function of pulmonary vasculature. Thereby, enhancing
l-citrullinemalate in patientswith idiopathic pulmonary arterial hypertension and thosewith congenital
heart disease identiﬁed as Eisenmenger Syndrome results in reduction of pulmonary hypertension.
Methods and subjects: In this clinical trial before and after study, we assigned 25 patients with arterial
pulmonary hypertension (idiopathic or Eisenmenger Syndrome) to receive l-citrulline malate 1g three
times daily for two weeks. The primary measurement was the change in exercise capacity, as considered
as a result of the total distance walked in six minutes, from baseline to week 2. We also assessed mean
pulmonary artery pressure, the change in the quality of life, and the change in pro-brain natriuretic
peptide (BNP) level. The study was not powered to evaluate mortality.
Results: The mean walking distance in six minutes was signiﬁcantly increased by about 44m
(p=0.005) after receiving l-citrullinemalate.Mean pulmonary artery pressure signiﬁcantly reduced from
83.34mmHg before receiving l-citrulline malate to 79.1mmHg after that (p=0.01). All dimensions of the
quality of life had statistical differences after receiving l-citrulline malate except limit due to physical
health, limit due to emotional health and social functioning (p>0.05). Finally, pro-BNP difference was
not statistically signiﬁcant (p=0.9).
Conclusion: l-Citrulline malate improves the distance walk in six minutes and also the quality of life of
patients with idiopathic arterial pulmonary hypertension and Eisenmenger Syndrome and also reduced
mean arterial pulmonary hypertension.
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Introduction
Pulmonary vascular tone is preserved as a result of the action
of vasoprotective compounds such as nitric oxide (NO) [1]. The
anion nitrite (NO2−) can produce NO endogenously in the body
by the use of l-arginine and aNOS-independent mechanism [2,3].
Citrulline is an alpha amino acid which is generated by the urea
cycle; through its metabolism endogenous NO can be formed. And
served.
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all 25 patients. Seventeen patients (74%) were female and eight32 B. Sharif Kashani et al. / Journ
t is metabolized to l-arginine in the vascular endothelium, kidney,
nd other cells. Oral administration of citrulline is more effective
han l-arginine in producing an increase in the blood levels of l-
rginine. As a result of not being a substrate for arginase, citrulline
oes not undergo intestinal or hepatic metabolism. So it does not
nduce its expression and activation. Therefore l-citrulline holds
romise in the treatmentof endothelial dysfunction, andperhapsof
ardiovascular disease, inwhich l-arginine deﬁciency and bioavail-
bility of NO are involved [4,5].
Cyclic guanosinemonophosphatewhich is the ultimate product
f NO results in vasodilatation of the pulmonary vasculature [6].
O as a vasodilator is important for the normal function of the
ulmonary vasculature. Loss of this mediator and the subsequent
ndothelial dysfunction is hypothesized to be a contributing reason
or progress of pulmonary hypertension [1].
An important category of patients with pulmonary arterial
ypertension (PAH) is idiopathic pulmonary arterial hypertension
IPAH) that has indeﬁnite etiology and is deﬁned by progressive
estruction of small- and medium-sized pulmonary arteries and
n increase in pulmonary arterial pressure and pulmonary vas-
ular resistance. Occurrence of these pathologies ﬁnally leads to
ight heart failure and death [7]. And recent studies demonstrated
hat, early determination of PAH can be done by simple exercise
chocardiography using the Master’s two-step test [8].
Another category is congenital heart disease such as Eisen-
enger Syndrome. In this category resistance of pulmonary
asculature is low and blood ﬂow of the vasculature is high [9–11].
ne of the therapeutic advances for IPAH is oral use of NO pre-
ursors, as a result of its vasodilatory features [12]. Efﬁcacy of
-arginine is well-tested in the literature but there is a lack of data
onsidering l-citrulline malate. Also based on other trials, com-
ination therapy of two types of oral drugs, endothelin receptor
ntagonists and phosphodiesterase V inhibitors is an improvement
n PAH therapy [13]. Therefore, this study will assess therapeutic
fﬁciency of l-citrulline malate in two categories of patients with
PAH and Eisenmenger Syndrome. This randomized clinical trial
mploys the 6-min walk test as a marker of functional improve-
ent of the patients, pulmonary arterial pressure (PAP), the quality
f life, and level of plasma pro-brain natriuretic peptide (BNP) in
hese patients.
ethods
atient selection
Patients with PAH (idiopathic, congenital systemic-
o-pulmonary shunts whether repaired or not) were included
n this study.
Pulmonary hypertension has been characterized as an aug-
entation in mean PAP ≥25mmHg at rest as evaluated by right
eart catheterization (RHC) [14,15]. A 7.5 F, balloon-tipped, ther-
odilution catheter was positioned in the pulmonary artery for
easurement of PAP, right atrial pressure, and pulmonary capil-
ary wedge pressure for subjects. Standard formulas were used to
alculate CI (cardiac index), systemic vascular resistance, and either
ulmonary vascular resistance (PVR= [mean PAP−pulmonary cap-
llary wedge pressure]/CO (cardiac output) or total pulmonary
esistance (TPR=mean PAP/CO)) if the wedge position could not
e reliably maintained.
Pulmonary pressureswere also anticipated byDoppler echocar-
iography with the following diagnostic criteria: (1) signiﬁcant
ricuspid regurgitation, (2) enlarged or hypertrophied right ventri-
le without evidence of pulmonary stenosis, or (3) intraventricular
eptal ﬂattening [16,17]. The ethics committee for human research
f Shahid Beheshti University of Medical Sciences has reviewed
nd accepted the entire study protocol. A written well-versedardiology 64 (2014) 231–235
permission was attained from all patients. Our study protocol
required all patients to continue their conventional therapy. The
study protocol was registered in clinicaltrial.gov and the identiﬁer
number is NCT01683981.
Exclusion criteria of this study were: patients older than
70 years, patients with a walking distance in six minutes which is
<100meters (m), active pulmonary or extra pulmonary infection,
serious coronaropathy and/or ventricular dysfunction, signiﬁcant
renal illness and/or hepatitis, detected immunosuppressive ill-
nesses, carrier of known neoplasias, pregnancy, not having family
support, psychosocial problems, drug or alcohol abuse, and nega-
tive response with established medical protocol.
Outcome measures
The primary measurement was the change in exercise capacity,
as measured by means of the total distance walked in six minutes,
from baseline to week 2. Other measurements were the changes
in mean PAP, also the change in the quality of life, and the change
in pro-BNP level. Quality of life measures were assessed according
to the Short Form (SF)-36 Health Survey questionnaire. Adverse
events were monitored throughout the study period.
Study protocol
Twenty-ﬁve patients were enrolled in this clinical trial, before
and after study at the PAH clinic in the National Research Institute
of Tuberculosis and Lung Disease (NRITLD) between August and
October of 2012. This study recruited 20 patients (4 males and 16
females) with IPAH and a functional class II or III according to the
diagnostic criteria deﬁned by the European Society of Cardiology
(ESC). This study also included 5 patients (3 males and 2 females)
withEisenmenger Syndromewithno complex congenital heart dis-
ease. All patients underwent an echocardiography as part of the
initial diagnostic work up even if they had been diagnosed as hav-
ing PAH. Furthermore, a six-minute walk test and a pro-BNP level
were taken. l-Citrulline 1g was administered as dry powder that
should be diluted in 250mg of water. Patients were followed for 2
weeks after being given l-citrulline malate 1g by the 6-min walk
test, pro-BNP level, and echocardiographic index such as PAP.
Statistical analysis
Continuous variables are presented as mean± SD. For the cate-
gorical variables frequency and percentagewere reported. The ﬁrst
and fourth end points, the six minute walking test and the level of
pro-BNPwereevaluatedwith theuseof aWilcoxon’s rank-sumtest.
The secondary end point (mean PAP) was assessed with indepen-
dent samples t-test. Quality of life was evaluated with chi-square
test. Statistical signiﬁcance was deﬁned as a p-value lower than
0.05. All data were analyzed with SPSS version 17 for Windows
(SPSS, Chicago, IL, USA).
Results
A total of 25patientswere assigned to receive l-citrullinemalate
at a dose of 1 g divided 3 times a day for two weeks.
Baseline characteristics
Baseline characteristics were not statistically different among(26%) were male (Table 1). The mean age of the patients was
31.2±9.27 years. The youngest participant was 18 years and the
oldest was 51 years. Two patients were excluded from the study
due to the adverse reactions of the prescribed drug.
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Table 1
Baseline characteristics of the patients.
Female (%) 17 (74%)
Age (years) (mean± SD) 31.2±9.27
6min walk (mean± SD) 351.6 (116.4)
PAP (mean± SD) 83.34 (22.4)
SF36 (mean± SD)
Physical functioning 61.5 (11.3)
Limit due to physical health 95.7 (14.4)
Limit due to emotional health 97.1 (9.5)
Energy-fatigue 54.8 (16.8)
Emotional well being 65.1 (7.8)
Social functioning 87.5 (0)
Pain 89.0 (15.9)
General health 60.0 (12.4)
Pro-BNP 339.7 (247.4)
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Table 2
Analysis of mean change of walking distance at 6min, pulmonary arterial pressure
and Short Form 36 from before to after receiving l-citrulline malate.
Mean difference before
receiving l-citrulline
malate–after receiving
l-citrulline malate (CI)
p-Value
Walking distance at 6min −44.1 (−73.2 to −15.1) 0.005
Pulmonary arterial pressure 4.2 (1.0–7.4) 0.01
SF36
Physical functioning −2.8 (−5.1 to −0.58) 0.02
Limit due to physical health Not changed –
Limit due to emotional health Not changed –
Energy-fatigue −5.4 (−7.9 to −3.0) <0.001
Emotional well being −0.95 (−1.8 to −0.1) 0.02
Social functioning Not changed –
Pain −2.2 (−4.0 to −0.4) 0.02
General health −2.0 (−3.2 to −0.7) 0.004AP, pulmonary arterial pressure; SF36, Short Form 36 Health Survey; BNP, brain
atriuretic peptide.
xercise capacity
Distance walked in six minutes was increased after receiving
-citrulline malate compared to baseline (p=0.005) (Table 2). No
tatistically signiﬁcant difference between males and females was
bserved in the distance in six-minute walk (p=0.34) (Fig. 1). Age
as the other variable that was shown to be independent of the
ean walked distance in six minutes before and after receiving
-citrulline (p=0.08) (Fig. 2).
ulmonary arterial pressure
Mean PAP before receiving l-citrulline malate (83.34mmHg)
Table 1), as compared to its level after the treatment period
79.1mmHg) (Table 1), was signiﬁcantly lower (p=0.01) (Table 2).
uality of lifeIn all dimensions of thequality of life questionnaire, after receiv-
ng l-citrulline malate, the obtained score was higher or it was
dentical to its baseline level (Table 1). There was a signiﬁcant
Fig. 1. Bar chart of walking distance at 6min before and aPro-BNP −2.4 (−76.8 to −72.0) 0.9
SF36, Short Form 36 Health Survey; BNP, brain natriuretic peptide.
difference between mean physical functioning (p=0.02), energy-
fatigue (p<0.001), emotional well-being (p=0.02), pain (p=0.02),
and general health (p=0.004) (Table 2). There were no changes
in dimensions such as limit due to physical health, limit due to
emotional health, and social functioning.
Pro-BNP
Comparing pro-BNP before with after receiving
l-citrulline malate, our results disclosed that it was higher
after receiving l-citrulline malate and the difference was not
statistically signiﬁcant (p=0.9) (Table 2).
SafetyMost adverse events were mild to moderate for all participants.
The encountered adverse reactions of l-citrulline malate in the
present study were edema in terminal limbs; urine frequency;
increased cough; and heartburn. These were seen in two patients.
fter using l-citrulline malate separated by gender.
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iscussion
In this before–after clinical trial, l-citrulline malate signiﬁ-
antly improved exercise capacity, as assessed according to the
ix-minute walking test, in patients with PAH, whether it was
diopathic or it was due to congenital systemic-to-pulmonary
hunts. This study was not designed to evaluate mortality. In the
ulmonary vasculature, NO is formed from the metabolism of l-
rginine to l-citrulline, two amino acids produced by the urea
ycle. l-Citrulline to l-arginine salvaging in endothelial cells by
he enzymes arginosuccinate synthetase and arginosuccinate lyase
s proposed to be the principal mechanism for sustaining local
-arginine availability for eNOS-catalyzedNOproduction [18]. Thus
ar, it has been shown that polymorphisms in the gene encod-
ng carbamoyl-phosphate synthetase 1, the enzyme that produces
-citrulline in the urea cycle, affects NO metabolite concentra-
ions and its subsequent vasodilation [19]. Previous evidence
uggests that in infants with persistent PAH of the newborn or
fter bypass surgery for congenital heart disease, plasma con-
entrations of arginine, citrulline, and NO metabolites are all
ow and this can be reversed by oral citrulline supplementation
20,21].
The distance walked in six minutes can be used as an indepen-
ent predictor of death in patients with IPAH [22] and has been
sed as the primarymeasurement inmost clinical trials concerning
atients with PAH [23]. The treatment-correlated augmentation in
ix minute walking test of 44m observed in this study is alike to
he increases observed with the use of oral bosentan (44m) [24]
nd is higher than the increase seen with the use of subcutaneous
reprostinil (16m) [25] and inhaled iloprost (36m) [26] and is less
han intravenous epoprostenol (47m) [27] and with the use of oral
ildenaﬁl citrate (45–50m) [28]. All patients in this study had PAH
f WHO class II or III, which is not a measure of the severity of their
ondition. Other trials demonstrate that the sickest patients (those
ith PAH of WHO class III or IV) had the greatest improvement
n the six-minute walking distance. Previous studies have shown
hat short-term administration of l-arginine can improve endothe-
ial dysfunction, which is related to increase exercise capacity in
atients with congestive heart failure [29,30].
Thus, it is also possible that the increase in exercise capac-
ty with l-citrulline malate, as compared to l-arginine, may belline malate separated by the mean age (upper and lower mean age).
partly attributable to improvement in endothelium-dependent
peripheral vasodilation in patients with PAH. Abnormalities in
endogenous vasodilator substances such asNOhavebeenproposed
as being important in thedevelopment of PAH [31–33]. Thebiologic
actions of l-arginine, the precursor of NO, have been examined
in a variety of cardiovascular diseases [29,34–36]. However, the
therapeutic potential of orally administered l-citrulline malate in
patients with PAH remains unknown.
The consequence of the oral supplementation of l-citrulline
malate was a signiﬁcant decrease in mean PAP and was similar to
that observed with intravenous epoprostenol [27] and oral bosen-
tan [24] in smaller studies. These ﬁndings suggest that l-citrulline
malate may cause pulmonary vasodilation at least partly via a NO-
mediated mechanism.
l-Citrulline malate also signiﬁcantly improved the quality of
life in these patients. Physical functioning, energy-fatigue, emo-
tional well-being, pain, and general health were all improved in
the present study. There were no changes in limits due to physical
health, limits due to emotional health and social functioning. This
study also demonstrated no reduction in pro-BNP plasma level of
thesepatients, but one-week supplementationof l-arginine tended
to decrease plasma atrial natriuretic peptide and BNP, potential
markers of right ventricular dysfunction [37,38]. With this dose of
l-citrullinemalate, themain adverse eventsweremild tomoderate
and were not clinically signiﬁcant. Intravenous epoprostenol has
shown complex delivery systems, signiﬁcant side effects, or both
(e.g. catheter-related infections, sepsis, and pump malfunctions)
[27], subcutaneous treprostinil (infusion-site pain) [25], inhaled
iloprost (multiple daily inhalations) [26], and oral bosentan (abnor-
malities of hepatic function) [24].
This study has certain limitations. Lack of a control group might
be named as the major pitfall of this study. Moreover, our patients
were selected from those with minimal disease progression and
hence our results cannot be extended to patientswith severe forms
of the disease. The short treatment period and not measuring lab-
oratory data such as NO pathway, nitrite/nitrate, or cGMP and
arginine metabolites in platelets were the other limitations of this
trial. More randomized controlled trials with larger sample size
with measurement of the NO pathway or arginine metabolites by
blood samples are needed to conﬁdently use our results in routine
practice.
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Short-term oral administration of l-citrulline malate modestly
ecreased PAH and improved exercise capacity and quality of
ife without serious adverse effects in patients with PAH (IPAH,
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he important end point of mortality.
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